Patents by Inventor Shawn QIAN

Shawn QIAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTIMODAL FREIGHT MONITORING AND CONTEXTUAL NOTIFICATION FOR DELIVERY VEHICLE
    Publication number: 20240140738
    Abstract: A multimodal freight monitoring and contextual notification system for a delivery vehicle. The system may include one or more monitoring systems configured to generate monitoring data for multimodal monitoring of freight included within a cargo bay of the delivery vehicle and a contextual notification controller configured to generate a contextual notification as a function thereof.
    Type: Application
    Filed: October 26, 2022
    Publication date: May 2, 2024
    Applicant: GM GLOBAL TECHNOLOGY OPERATIONS LLC
    Inventors: Alaa M. Khamis, Yun Qian Miao, Christopher L. Oesterling, Derek B. Ancrum, Shawn F. Granda
  • THERAPEUTIC INHIBITORY COMPOUNDS
    Publication number: 20210395221
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Application
    Filed: September 21, 2020
    Publication date: December 23, 2021
    Inventors: Andrew MCDONALD, Shawn QIAN
  • Therapeutic inhibitory compounds
    Patent number: 11021463
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: June 1, 2021
    Assignee: ATTUNE PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian
  • Therapeutic inhibitory compounds
    Patent number: 10981893
    Abstract: Provided herein are heterocyclic derivative compounds of Formula (I) and pharmaceutical compositions comprising said compounds. The compounds of Formula (I) are useful for inhibiting plasma kallikrein. Furthermore, the disclosed compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: April 20, 2021
    Assignee: ATTUNE PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian
  • TREATMENT OF HEREDITARY ANGIOEDEMA
    Publication number: 20200405708
    Abstract: Described herein are compositions comprising a highly selective at plasma kallikrein inhibitor and useful for the treatment of angioedema.
    Type: Application
    Filed: February 28, 2019
    Publication date: December 31, 2020
    Inventors: Andrew MCDONALD, Shawn QIAN, Ira KALFUS
  • Therapeutic inhibitory compounds
    Patent number: 10781200
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: September 22, 2020
    Assignee: ATTUNE PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian
  • THERAPEUTIC INHIBITORY COMPOUNDS
    Publication number: 20200239435
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Application
    Filed: April 11, 2019
    Publication date: July 30, 2020
    Inventors: Andrew MCDONALD, Shawn QIAN
  • THERAPEUTIC INHIBITORY COMPOUNDS
    Publication number: 20200031799
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Application
    Filed: April 2, 2019
    Publication date: January 30, 2020
    Inventors: Andrew MCDONALD, Shawn QIAN
  • THERAPEUTIC INHIBITORY COMPOUNDS
    Publication number: 20200031800
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Application
    Filed: April 2, 2019
    Publication date: January 30, 2020
    Inventors: Andrew MCDONALD, Shawn QIAN
  • THERAPEUTIC INHIBITORY COMPOUNDS
    Publication number: 20190292155
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. Said heterocyclic derivative compounds are complement factor D inhibitors. Such compounds are useful for treating complement related disorders including, but are not limited to, autoimmune, inflammatory, and neurodegenerative diseases.
    Type: Application
    Filed: July 14, 2017
    Publication date: September 26, 2019
    Inventors: Andrew MCDONALD, Shawn QIAN
  • THERAPEUTIC INHIBITORY COMPOUNDS
    Publication number: 20190263783
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subjuect compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Application
    Filed: June 30, 2016
    Publication date: August 29, 2019
    Inventors: Andrew McDonald, Shawn Qian
  • THERAPEUTIC INHIBITORY COMPOUNDS
    Publication number: 20190263818
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Application
    Filed: June 30, 2016
    Publication date: August 29, 2019
    Inventors: Andrew McDonald, Shawn Qian
  • Therapeutic inhibitory compounds
    Patent number: 10308637
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: June 4, 2019
    Assignee: LIFESCI PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian
  • Therapeutic inhibitory compounds
    Patent number: 10301284
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: May 28, 2019
    Assignee: LIFESCI PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian
  • THERAPEUTIC INHIBITORY COMPOUNDS
    Publication number: 20190127366
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds which are complement factor D inhibitors. Such compounds are useful for treating complement related disorders including, but are not limited to, autoimmune, inflammatory, and neurodegenerative diseases.
    Type: Application
    Filed: December 9, 2016
    Publication date: May 2, 2019
    Inventors: Andrew MCDONALD, Shawn QIAN
  • Therapeutic inhibitory compounds
    Patent number: 10266515
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: April 23, 2019
    Assignee: LIFESCI PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian
  • Therapeutic inhibitory compounds
    Patent number: 10259803
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: April 16, 2019
    Assignee: LIFESCI PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian
  • THERAPEUTIC INHIBITORY COMPOUNDS
    Publication number: 20190002437
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Application
    Filed: June 14, 2018
    Publication date: January 3, 2019
    Inventors: Andrew MCDONALD, Shawn QIAN
  • THERAPEUTIC INHIBITORY COMPOUNDS
    Publication number: 20180297984
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Application
    Filed: June 22, 2018
    Publication date: October 18, 2018
    Inventors: Andrew MCDONALD, Shawn QIAN
  • Therapeutic inhibitory compounds
    Patent number: 10023557
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: July 17, 2018
    Assignee: LIFESCI PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian